Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism

Clin Endocrinol (Oxf). 2022 Feb;96(2):200-219. doi: 10.1111/cen.14633. Epub 2021 Nov 22.

Abstract

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and variations in its diagnosis and management exist. There are several current guidelines on testosterone replacement therapy that have been driven predominantly by single disciplines. The Society for Endocrinology commissioned this new guideline to provide all care providers with a multidisciplinary approach to treating patients with MH. This guideline has been compiled using expertise from endocrine (medical and nursing), primary care, clinical biochemistry, urology and reproductive medicine practices. These guidelines also provide a patient perspective to help clinicians best manage MH.

Keywords: diagnosis treatment and monitoring; guidance, male hypogonadism; sexual dysfunction; testis, testosterone.

MeSH terms

  • Endocrine System Diseases*
  • Endocrinology*
  • Hormone Replacement Therapy
  • Humans
  • Hypogonadism* / drug therapy
  • Male
  • Testosterone / therapeutic use

Substances

  • Testosterone